Sign in

You're signed outSign in or to get full access.

Priyanka

Vice President and Equity Research Analyst at JPMorgan Chase & Co.

Priyanka Patel is a Vice President and Equity Research Analyst at JPMorgan Chase & Co., specializing in the healthcare sector with a focus on biotechnology and pharmaceuticals. She covers key companies including Regeneron Pharmaceuticals, Vertex Pharmaceuticals, BioMarin Pharmaceutical, and Alnylam Pharmaceuticals, boasting a strong performance track record with a 68% success rate on TipRanks and average return of 22% per rating over the past few years. Patel joined JPMorgan in 2018 after previous roles at Barclays Capital from 2014 to 2018 and starting her career at Leerink Partners in 2012, holding a CFA charter and FINRA Series 7 and 63 licenses. Her insightful calls have earned her recognition in the top 10% of biotech analysts on institutional investor platforms.

Priyanka's questions to RECURSION PHARMACEUTICALS (RXRX) leadership

Question · Q4 2025

Priyanka from JPMorgan Chase & Co. asked for clarification on the potential registrational pathway for REC-4881, including FDA alignment, regulatory updates, and patient population considerations.

Answer

Najat Khan, CEO and President, confirmed the company is on track for initial FDA engagement in H1 2026 to discuss registrational study design, patient population, and endpoints, leveraging compelling durability and polyp burden reduction data, along with natural history data. She also noted the 18-and-over cohort is recruiting, and dose optimization efforts are underway, with more data expected in H1 2027.

Ask follow-up questions

Fintool

Fintool can predict RECURSION PHARMACEUTICALS logo RXRX's earnings beat/miss a week before the call